The International Accreditation System for Interventional Oncology Services (IASIOS) has announced the accreditation of Centre hospitalier de l’Université de Montréal (CHUM) in Montreal, becoming the first centre in Canada to achieve this.
In a recent press release, IASIOS states that this achievement reflects CHUM’s strong commitment to delivering high-quality, standardised, and patient-centred interventional oncology (IO) care. IO offers minimally invasive, image-guided treatments that complement surgery, systemic therapies, and radiation, contributing to more precise and personalised cancer care. As one of Canada’s leading academic institutions, CHUM plays a key role in advancing multidisciplinary cancer treatment, and its accreditation marks an important step in aligning its IO services with internationally recognised best practices.
IASIOS was established to support the development and standardisation of IO services worldwide, ensuring safe, effective, and consistent care across the entire patient pathway. By achieving IASIOS accreditation, CHUM has demonstrated full compliance with the rigorous international standards defined in the Cardiovascular and Interventional Society of Europe (CIRSE) Standards of Quality Assurance in Interventional Oncology. These standards provide a comprehensive framework covering staff and facilities, treatment planning and delivery, and safety and quality, ensuring optimal patient outcomes.
According to IASIOS, this milestone not only represents an institutional achievement but also sets a benchmark for interventional oncology services across Canada. As the first IASIOS Accredited Centre in the country, CHUM paves the way for other institutions to follow, supporting the broader adoption of structured, high-quality IO care, the press release continues.
Ricardo Holderbaum Do Amaral, assistant clinical professor in the Department of Radiology, Radiation Oncology and Nuclear Medicine, faculty of medicine at University of Montreal and interventional radiologist at CHUM, is leading the accreditation process, supporting the centre’s efforts to further develop and standardise its IO pathway.
“This accreditation reflects the rigorous work of our teams and our ongoing commitment to delivering excellence in care. In interventional oncology, our vision is clear: to provide treatments that are increasingly precise, safe, and tailored to the population we serve. At CHUM, we place patients at the heart of every decision, relying on innovation, interdisciplinary collaboration, and continuous improvement to sustainably enhance cancer care,” said Amaral.
